substance use disorder treatment, employers, and patients or their advocates. Written comments may be submitted to parity@hhs.gov for two weeks prior to the meeting through August 10, 2017.

DATES: The meeting will be held on July 27, 2017 from 9:30 a.m. to 11:30 a.m. EDT.

ADDRESSES: The meeting will be held in the first floor auditorium in the Hubert H. Humphrey Building, 200 Independence Avenue SW., Washington, DC 20201.

Comments: The time for oral comments will be limited to five (5) minutes per individual. In lieu of oral comments, formal written comments may be submitted for the record to Laurel Fuller, ASPE, 200 Independence Avenue SW., Room 424E, Washington, DC 20201; all comments should be submitted to parity@hhs.gov. Those submitting comments should identify themselves and any relevant organizational affiliations.

FOR FURTHER INFORMATION CONTACT: Laurel Fuller (202) 690–5949, Laurel.Fuller@hhs.gov.

SUPPLEMENTARY INFORMATION:
Procedure and Agenda: This meeting is open to the public. Please allow 45 minutes to go through security and walk to the meeting room. The meeting will also be webcast at www.hhs.gov/live.

Note: Seating will be limited to 75 attendees; this listening session will also be webcast online at www.hhs.gov/live. Those wishing to attend the meeting must send an email to parity@hhs.gov and put “July 27 Public Meeting” in the Subject line by Friday, July 21, 2017 so that their names may be put on a list of expected attendees and forwarded to the security officers the Humphrey Building. In the email please also indicate which group you are representing (State health commissioners, State agencies, State attorneys general, the National Association of Insurance Commissioners, health insurance issuers, providers of mental health and substance use disorder treatment, employers, and patients or their advocates; or other). Any interested member of the public who is a non-U.S. citizen should include this information at the time of registration to ensure that the appropriate security procedure to gain entry to the building is carried out. Although the meeting is open to the public, procedures governing security and the entrance to federal buildings may change without notice. If you wish to make a public comment, you must note that within your email.


John R. Graham,
Acting Assistant Secretary for Planning and Evaluation.

BILLING CODE 4150–15–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Diabetes and Digestive and Kidney Diseases Special Emphasis Panel; Review of K24 Application.
Date: July 25, 2017.
Time: 11:00 a.m. to 1:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Two Democracy Plaza, 6707 Democracy Boulevard, Bethesda, MD 20892 (Telephone Conference Call).
Contact Person: Barbara A. Woynarowska, Ph.D., Scientific Review Officer, Review Branch, DEA, NIDDK, National Institutes of Health, Room 754, 6707 Democracy Boulevard, Bethesda, MD 20892–5452, (301) 402–7172, woynarowskab@niddk.nih.gov.

Date: August 7, 2017.
Time: 1:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Two Democracy Plaza, 6707 Democracy Boulevard, Bethesda, MD 20892 (Telephone Conference Call).
Contact Person: Ann A. Jenkins, Ph.D., Scientific Review Officer, Review Branch, DEA, NIDDK, National Institutes of Health, Room 7119, 6707 Democracy Boulevard, Bethesda, MD 20892–5452, (301) 594–2242, jenkinsa@niddk.nih.gov.

Name of Committee: National Institute of Diabetes and Digestive and Kidney Diseases Special Emphasis Panel; Limited Competition: Data Coordinating Center for Type 1 Diabetes TrialNet (UC4).
Date: August 15, 2017.
Time: 1:00 p.m. to 2:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Two Democracy Plaza, 6707 Democracy Boulevard, Bethesda, MD 20892 (Telephone Conference Call).
Contact Person: Paul A. Rushing, Ph.D., Scientific Review Officer, Review Branch, DEA, NIDDK, National Institutes of Health, Room 7345, 6707 Democracy Boulevard, Bethesda, MD 20892–5452, (301) 594–8895, rushingp@extra.niddk.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.847, Diabetes, Endocrinology and Metabolic Research; 93.848, Digestive Diseases and Nutrition Research; 93.849, Kidney Diseases, Urology and Hematology Research, National Institutes of Health, HHS)

Dated: June 27, 2017.

David Clary,
Program Analyst, Office of Federal Advisory Committee Policy.

BILLY CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Amended Notice of Meeting

Notice is hereby given of a change in the meeting of the National Cancer Institute Special Emphasis Panel, July 12, 2017, 11:00 a.m. to July 12, 2017, 3:00 p.m., National Cancer Institute Shady Grove, Shady Grove, 9609 Medical Center Drive, 7W114, Rockville, MD 20850 which was published in the Federal Register on May 31, 2017, 82 FR 24983.

The meeting notice is amended to change the meeting title to “Biospecimen and Innovative Technology”. The meeting is closed to the public.

Dated: June 27, 2017.

Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory Committee Policy.

BILLY CODE 4140–01–P